<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents – A2</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents – A2</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents – A2</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lloyd Axelrod, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">ANSWER</span><span class="headingEndMark"> — </span>Incorrect.</p><p>The choice of a pharmacologic agent when lifestyle change and maximum tolerated doses of two oral agents do not achieve target glycemia should be individualized (see  <a class="medical medical_review" href="/d/html/1790.html" rel="external">"Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'Dual agent failure'</a>). This patient does not have established atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease, so there is no strong indication for a glucagon-like peptide 1 (GLP-1) receptor agonist or a sodium-glucose cotransporter 2 (SGLT2) inhibitor [<a href="#rid1">1</a>]. Cost is a major concern for this patient, so a basal insulin with a low acquisition cost is preferable.</p><p><a class="drug drug_general" data-topicid="9005" href="/d/drug information/9005.html" rel="external">Exenatide</a> (synthetic exendin-4) is a GLP-1 agonist.</p><p>GLP-1, 7-37, a naturally occurring peptide produced by the L-cells of the small intestine, stimulates endogenous insulin secretion. <a class="drug drug_general" data-topicid="9005" href="/d/drug information/9005.html" rel="external">Exenatide</a>, which is structurally homologous with GLP-1, has the same effect, but has a longer circulating half-life than GLP-1 and is suitable for clinical use. It is administered by subcutaneous injection twice a day before meals. Exenatide also reduces glucagon secretion and decreases gastric motility. Its effect on glucose levels is predominantly postprandial. Exenatide reduces glycated hemoglobin (A1C) values by approximately 1.0 percent  (<a class="graphic graphic_table graphicRef138312" href="/d/graphic/138312.html" rel="external">table 1</a>).</p><p><a class="drug drug_general" data-topicid="9005" href="/d/drug information/9005.html" rel="external">Exenatide</a> causes gastrointestinal (GI) side effects (notably nausea, vomiting, and diarrhea) in a large proportion of patients. Its use is associated with modest weight loss, due at least in part to the GI side effects. (Occasionally a patient will experience appreciable weight loss.) It should not be used in patients with gastroparesis. It is expensive.</p><p>The US Food and Drug Administration (FDA) issued an alert about a possible association of incretin-based drugs such as <a class="drug drug_general" data-topicid="9005" href="/d/drug information/9005.html" rel="external">exenatide</a> (and <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a>) with acute pancreatitis based upon a review of 30 postmarketing reports, in some of which a causal relationship between these agents and acute pancreatitis was suspected. The FDA and the European Medicines Agency now agree that there is insufficient evidence to confirm an increased risk of pancreatitis or pancreatic cancer with the use of GLP-1-based therapies [<a href="#rid2">2</a>]. Pancreatitis continues to be considered a risk associated with these drugs. Concerns remain, and monitoring for and reporting of pancreatic adverse effects continues. Exenatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with the multiple endocrine neoplasia syndrome type 2.</p><p>If a GLP-1 receptor agonist is chosen because of the presence of known ASCVD, the strongest evidence is for <a class="drug drug_general" data-topicid="97148" href="/d/drug information/97148.html" rel="external">dulaglutide</a>, <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a>, and <a class="drug drug_general" data-topicid="115980" href="/d/drug information/115980.html" rel="external">semaglutide</a> [<a href="#rid1">1</a>].</p><p>Return to the beginning to try again. (See  <a class="medical medical_review" href="/d/html/4176.html" rel="external">"Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S140.</a></li><li><a class="nounderline abstract_t">Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med 2014; 370:794.</a></li></ol></div><div id="topicVersionRevision">Topic 4211 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36507650" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24571751" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pancreatic safety of incretin-based drugs--FDA and EMA assessment.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
